Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022;20(7):1383-1399.
doi: 10.2174/1570159X20999220131163504.

Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?

Matthew A Smith-Cohn  1 , Nicholas B Burley  2 , Stuart A Grossman  3
Affiliations
Review

Transient Opening of the Blood-Brain Barrier by Vasoactive Peptides to Increase CNS Drug Delivery: Reality Versus Wishful Thinking?

Matthew A Smith-Cohn et al. Curr Neuropharmacol. 2022.

Abstract

Background: The blood-brain barrier inhibits the central nervous system penetration of 98% of small molecule drugs and virtually all biologic agents, which has limited progress in treating neurologic disease. Vasoactive peptides have been shown in animal studies to transiently disrupt the blood-brain barrier and regadenoson is currently being studied in humans to determine if it can improve drug delivery to the brain. However, many other vasoactive peptides could potentially be used for this purpose.

Methods: We performed a review of the literature evaluating the physiologic effects of vasoactive peptides on the vasculature of the brain and systemic organs. To assess the likelihood that a vasoactive peptide might transiently disrupt the blood-brain barrier, we devised a four-tier classification system to organize the available evidence.

Results: We identified 32 vasoactive peptides with potential blood-brain barrier permeabilityaltering properties. To date, none of these are shown to open the blood-brain barrier in humans. Twelve vasoactive peptides increased blood-brain barrier permeability in rodents. The remaining 20 had favorable physiologic effects on blood vessels but lacked specific information on permeability changes to the blood-brain barrier.

Conclusion: Vasoactive peptides remain an understudied class of drugs with the potential to increase drug delivery and improve treatment in patients with brain tumors and other neurologic diseases. Dozens of vasoactive peptides have yet to be formally evaluated for this important clinical effect. This narrative review summarizes the available data on vasoactive peptides, highlighting agents that deserve further in vitro and in vivo investigations.

Keywords: Blood-brain barrier; drug delivery; metastasis; neuro-oncology; neurology; oncology; pharmacokinetics; vasoactive peptides.

PubMed Disclaimer

References

    1. Pardridge W.M. Treatment of Alzheimer’s disease and blood-brain barrier drug delivery. Pharmaceuticals (Basel) 2020;13(11):394. doi: 10.3390/ph13110394. - DOI - PMC - PubMed
    1. Smith-Cohn M.A., Celiku O., Gilbert M.R. Molecularly targeted clinical trials. Neurosurg. Clin. N. Am. 2021;32(2):191–210. doi: 10.1016/j.nec.2020.12.002. - DOI - PubMed
    1. O’Connell K., Romo C.G., Grossman S.A. Brain metastases as a first site of recurrence in patients receiving chemotherapy with con-trolled systemic cancer: A critical but under-recognized clinical scenario. Curr. Treat. Options Neurol. 2019;21(11):55. doi: 10.1007/s11940-019-0598-6. - DOI - PubMed
    1. Krueger M., Mages B., Hobusch C., Michalski D. Endothelial edema precedes blood-brain barrier breakdown in early time points after experimental focal cerebral ischemia. Acta Neuropathol. Commun. 2019;7(1):17. doi: 10.1186/s40478-019-0671-0. - DOI - PMC - PubMed
    1. Abrahao A., Meng Y., Llinas M., Huang Y., Hamani C., Mainprize T., Aubert I., Heyn C., Black S.E., Hynynen K., Lipsman N., Zinman L. First-in-human trial of blood-brain barrier opening in amyotrophic lateral sclerosis using MR-guided focused ultrasound. Nat. Commun. 2019;10(1):4373. doi: 10.1038/s41467-019-12426-9. - DOI - PMC - PubMed